Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Poku

Clinical Cardiac Electrophysiology Macon, GA Medical Doctor

NPI 1902980527 CMS profile 313701

639 Hemlock St, Suite 100, Macon, GA 31201

Open in the dashboard

General payments

$130,051

562 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Poku of Macon, GA is reported in the CMS Open Payments database as having received $130,051 across 562 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,714 51
2024 General $4,354 81
2023 General $19,045 96
2022 General $15,539 77
2021 General $5,292 70
2020 General $14,754 50
2019 General $69,353 137

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Poku
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Joseph Poku were reported at $1,714. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Joseph Poku Clinical Cardiac Electrophysiology median Middle half National median
2019 $69,353 $2,361 $585–$8,260 $163
2020 $14,754 $993 $247–$4,351 $114
2021 $5,292 $1,185 $326–$4,739 $132
2022 $15,539 $2,073 $554–$6,789 $149
2023 $19,045 $2,568 $759–$8,159 $160
2024 $4,354 $2,557 $703–$7,403 $164
2025 $1,714 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $88,394 158 payments
  2. Biotronik Inc. $18,451 15 payments
  3. Medtronic, Inc. $3,982 46 payments
  4. Pfizer Inc. $3,434 41 payments
  5. Biosense Webster, Inc. $3,047 7 payments
  6. Abbott Laboratories $3,043 18 payments
  7. Medtronic Vascular, Inc. $2,083 13 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,047 39 payments
  9. Boston Scientific Corporation $917 23 payments
  10. E.R. Squibb & Sons, L.L.C. $743 48 payments
  11. Other $4,910 154 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $81,375 30 payments
  2. Travel and Lodging $26,414 41 payments
  3. Food and Beverage $15,683 485 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $4,000 2 payments
  5. Consulting Fee $2,550 2 payments
  6. Education $29 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $88,394 158 payments
  2. ELIQUIS $3,253 35 payments
  3. Carto 3 $2,927 6 payments
  4. AVEIR Cardiac Rhythm Management $2,294 7 payments
  5. MICRA Pacemakers $1,763 7 payments
  6. EVERA MRI XT DR SURESCAN $1,350 11 payments
  7. Micra Pacemakers $1,184 10 payments
  8. LifeVest $1,047 39 payments
  9. VERQUVO $587 30 payments
  10. AVEIR Cardiac Rhythm Management $540 4 payments
  11. Other $7,845 271 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

5,894

Median for Cardiology: 2,533

Drug cost

$2,079,284

Median for Cardiology: $485,213

Branded share of claims

50.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 575 $511,686
Xarelto Rivaroxaban Brand 533 $445,784
Entresto Sacubitril/Valsartan Brand 356 $358,419
Farxiga Dapagliflozin Propanediol Brand 371 $258,362
Jardiance Empagliflozin Brand 252 $224,031
Ozempic Semaglutide Brand 43 $69,971
Multaq Dronedarone Hcl Brand 32 $40,901
Mounjaro Tirzepatide Brand 29 $30,900
Corlanor Ivabradine Hcl Brand 33 $23,114
Verquvo Vericiguat Brand 17 $21,333

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$281,029

Medicare's payments for the services billed

Medicare patients

643

Average age 77

Services billed

2,876

330 women, 313 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 72%
Heart failure 58%
Ischemic heart disease 58%
Chronic kidney disease 53%
Arthritis 49%
Diabetes 48%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $212
$212 533 —
VERQUVO
  • Merck Sharp & Dohme Corporation $156
$156 17 —
FUROSCIX
  • SCPHARMACEUTICALS INC. $126
$126 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $85
$85 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $72
$72 371 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

562 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record